SGLT-2i临床心血管保护作用及机制研究进展  

Research progress on clinical cardiovascular protective effect andmechanism of SGLT-2 inhibitors

作　　者：葛学婉 吴妍[2] 郭沫 高杉 GE Xue-wan;WU Yan;GUO Mo;GAO Shan(Dept of Pharmacology,School of Basic Medical Sciences,Anhui Medical University,Hefei 230032,China;Dept of Pharmacy,the First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230001,China;the Second Clinical Medical College,Anhui Medical University,Hefei 230032,China)

机构地区：[1]安徽医科大学基础医学院药理学教研室,安徽合肥230032 [2]中国科学技术大学附属第一医院(安徽省立医院)药学部,安徽合肥230001 [3]安徽医科大学第二临床医学院,安徽合肥230032

出　　处：《中国药理学通报》2025年第3期401-406,共6页Chinese Pharmacological Bulletin

基　　金：国家自然科学基金面上项目(No 81873126)。

摘　　要：钠-葡萄糖协同转运蛋白2抑制剂(sodium-glucose cotransporter 2 inhibitors,SGLT-2i)最初作为新型口服降糖药而研发上市。目前,已被国内外指南推荐为慢性心力衰竭(heart failure,HF)的主要治疗药物之一,对射血分数降低的心衰、射血分数改善的心衰、射血分数轻度降低的心衰及射血分数保留的心衰都具有显著的心血管保护作用。然而心脏组织并不表达钠-葡萄糖协同转运蛋白2(sodium glucose cotransporter 2,SGLT-2),SGLT-2i临床心血管获益的潜在机制仍不清楚。该综述拟概述SGLT-2i在临床试验中的心血管获益以及国内外HF指南的推荐建议,进一步阐述SGLT-2i介导的心血管保护作用的潜在机制。Sodium-glucose cotransporter 2 inhibitor was initially developed and marketed as a novel oral hypoglycemic agent.Currently,it has been recommended as one of the main therapeutic agents for chronic heart failure by national and international guidelines,and it has a significant cardioprotective effect on heart failure with reduced ejection fraction,heart failure with improved ejection fraction,heart failure with mildly reduced ejection fraction,and heart failure with preserved ejection fraction.However,cardiac tissues do not express sodium-glucose cotransporter 2,and the underlying mechanisms of clinical cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors remain unclear.This review intends to summarize the cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in clinical trials and the recommendations suggested by national and international heart failure guidelines and to elucidate further the potential mechanisms of sodium-glucose cotransporter 2 inhibitor-mediated cardioprotective effects.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 心力衰竭 心血管保护作用 

分 类 号：R54[医药卫生—心血管疾病] R541.61[医药卫生—内科学] R972.1[医药卫生—临床医学]